Simulect (basiliximab) / Novartis - LARVOL DELTA

Ten Years Ago, I Would've Called This... (USCAP 2026) - "Received second kidney transplant 2.5 years ago from living related donor (half-sister) with the following details: induction immunosuppression with basiliximab and methylprednisolone, cPRA 0%, HLA T and B cell flow cytometry crossmatch negative, CMV D+/R+, EBV D+/R+...No complications post-transplant, discharged home with standard triple-therapy maintenance immunosuppression (tacrolimus, MMF, prednisone), infection prophylaxis, and post-transplant follow-up... The current recommended terminology for transplant kidney biopsies showing g + ptc ≥ 2 but negative C4d and absence of identifiable HLA-DSA is "Microvascular inflammation, DSA-negative and C4d-negative. Using this standardized terminology for these ambiguous cases will facilitate further research into the underlying etiologies and targeted therapeutic approaches required for non-DSA-related microvascular injury. Evening Specialty Presentation (PDF): Click to View"

Antibody-mediated Rejection • Cardiovascular • Fibrosis • Glomerulonephritis • Immunology • Infectious Disease • Inflammation • Influenza • Lupus Nephritis • Nephrology • Reperfusion Injury • Respiratory Diseases • Solid Organ Transplantation

PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKAEMIA UNDERGOING UNMANIPULATED G-CSF–PRIMED HAPLOIDENTICAL BONE MARROW TRANSPLANTATION: FAVOURABLE LONG-TERM OUTCOME IN FIRST REMISSION WITH POSITIVE MEASURABLE RESIDUAL DISEASE (EBMT 2026) - "Advances in graft-versus-host disease (GVHD) prophylaxis have markedly improved safety—particularly through ATG-based and post–cyclophosphamide platforms—broadening access to transplantation for patients lacking an HLA-identical donor...The policy of donor selection, conditioning regimen including thiotepa-busulfan-fludarabine, graft source, supportive care, and infections prophylaxis were uniform across the cohort... In this homogeneously treated population of adults with high-risk AML, unmanipulated G-CSF–primed haploidentical bone marrow transplantation with ATG and Basiliximab based prophylaxis yielded excellent long-term outcomes despite the moderately high NRM and the unfavorable disease-risk features. These results indicate that, while NRM remains a significant limitation, this strategy represents a valuable therapeutic option for appropriately selected high-risk AML patients—particularly when applied in first remission, even in patients with MRD+."

Clinical • Residual disease • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Transplantation

COMBINATION OF 7.5 MG/KG ATG WITH BASILIXIMAB AS AN EFFECTIVE REGIMEN FOR PATIENTS WITH SEVERE INFUSIONAL SIDE EFFECTS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (EBMT 2026) - "Overall, the combination of 7.5 mg/kg ATG with basiliximab represents a feasible and effective protocol for treating patients who develop severe ISE during ATG treatment."

Adverse events • Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Immunology • Transplantation • ATG10 • IL2RA • ISG20

MESENCHYMAL STROMAL CELLS FOR THE TREATMENT STEROID REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN (EBMT 2026) - "In 19/20 patients before MSC administration combined therapy with corticosteroids was performed including 1-3 agent/therapy (ciclosporine, tacrolimus, mycophenolate mofetil, vedolizumab, ruxolitinib, basiliximab, extracorporeal photophereses). Cryopreserved Wharton's jelly mesenchymal stromal cells area safe and effective therapeutic option in pediatric patients with steroid refractory acute or chronic GVHD. Overall, 75% of patients achieved clinical response."

Clinical • Stroma • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • CNS Disorders • Graft versus Host Disease • Immunology • Infectious Disease • Primary Immunodeficiency • Scleroderma • Systemic Sclerosis

VEDOLIZUMAB FOR TREATING STEROID-REFRACTORY LOWER GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE: A SINGLE-CENTER REAL-WORLD STUDY (EBMT 2026) - "All patients received VDZ in combination with basiliximab, as second-line therapy in 42.8% and as third-line therapy in 57.2%. VDZ demonstrated substantial efficacy and a favorable safety profile as second- or third-line therapy for SR-LGI-aGVHD. Treatment response correlated more closely with baseline GVHD severity than the timing of intervention. VDZ was associated with a distinct immunological profile, leading to rapid and durable remission, improved survival, and reduced steroid dependence."

Clinical • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases • IL5 • ITGA4

PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKAEMIA UNDERGOING UNMANIPULATED G-CSF–PRIMED HAPLOIDENTICAL BONE MARROW TRANSPLANTATION: FAVOURABLE LONG-TERM OUTCOME IN FIRST REMISSION WITH POSITIVE MEASURABLE RESIDUAL DISEASE (EBMT 2026) - "Advances in graft-versus-host disease (GVHD) prophylaxis have markedly improved safety—particularly through ATG-based and post–cyclophosphamide platforms—broadening access to transplantation for patients lacking an HLA-identical donor...The policy of donor selection, conditioning regimen including thiotepa-busulfan-fludarabine, graft source, supportive care, and infections prophylaxis were uniform across the cohort... In this homogeneously treated population of adults with high-risk AML, unmanipulated G-CSF–primed haploidentical bone marrow transplantation with ATG and Basiliximab based prophylaxis yielded excellent long-term outcomes despite the moderately high NRM and the unfavorable disease-risk features. These results indicate that, while NRM remains a significant limitation, this strategy represents a valuable therapeutic option for appropriately selected high-risk AML patients—particularly when applied in first remission, even in patients with MRD+."

Clinical • Residual disease • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Transplantation

MESENCHYMAL STROMAL CELLS FOR THE TREATMENT STEROID REFRACTORY GRAFT-VERSUS-HOST DISEASE IN CHILDREN (EBMT 2026) - "In 19/20 patients before MSC administration combined therapy with corticosteroids was performed including 1-3 agent/therapy (ciclosporine, tacrolimus, mycophenolate mofetil, vedolizumab, ruxolitinib, basiliximab, extracorporeal photophereses). Cryopreserved Wharton's jelly mesenchymal stromal cells area safe and effective therapeutic option in pediatric patients with steroid refractory acute or chronic GVHD. Overall, 75% of patients achieved clinical response."

Clinical • Stroma • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • CNS Disorders • Graft versus Host Disease • Immunology • Infectious Disease • Primary Immunodeficiency • Scleroderma • Systemic Sclerosis

COMBINATION OF 7.5 MG/KG ATG WITH BASILIXIMAB AS AN EFFECTIVE REGIMEN FOR PATIENTS WITH SEVERE INFUSIONAL SIDE EFFECTS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (EBMT 2026) - "Overall, the combination of 7.5 mg/kg ATG with basiliximab represents a feasible and effective protocol for treating patients who develop severe ISE during ATG treatment."

Adverse events • Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Immunology • Transplantation • ATG10 • IL2RA • ISG20

REVEALING THE HIDDEN THREATS: SURVEILLANCE BIOPSY FINDINGS FROM LIVING DONOR KIDNEY TRANSPLANTATION IN NEPAL (ISN-WCN 2026) - "Characteristics of surveillance biopsy populationSNoCharacteristicFindings (N=119)1Mean age at transplantation (years)34.852SexMale88 (73.95%)Female31 (26.05%)3HLA Mismatch Level010 (8.4%)3/634 (28.57%)4Cause of ESRDUndetermined82(68.91%)IgAN18(15.13%)PCKD1(0.84%)Obstructive4(3.36%)Membranous Nephropathy1(0.84%)DKD5(4.20%)FSGS5(4.20%)Analgesis Nephropathy1(0.84%)Anti-GBM Disease1(0.84%)ANCA Vasculitis1(0.84%)5Average tacrolimus trough level (ng/ml)at 1 month10.783at 3 months9.443at 6 months8.24at biopsy7.336Induction agentATG111Basiliximab87Donor relationParent57Spouse32Sibling17Other13ATG, Anti-thymocyte globulin; ANCA, antineutrophil cytoplasmic antibodies; DKD, diabetic kidney disease; ESRD, end stage renal disease; FSGS, focal segmental glomerulosclerosis; GBM, glomerular basement membrane; GN, glomerulonephritis; HLA, human leucocyte antigen; IgAN, Immunoglobulin A Nephropathy, MPGN, membranoproliferative glomerulonephritis; PCKD, polycystic kidney disease; Biopsy..."

Biopsy • ANCA Vasculitis • Chronic Kidney Disease • Diabetic Nephropathy • Focal Segmental Glomerulosclerosis • Genetic Disorders • Glomerulonephritis • IgA Nephropathy • Infectious Disease • Lupus Nephritis • Nephrology • Polycystic Kidney Disease • Transplantation

BRIDGING THE DONOR GAP: CLINICAL AND SOCIODEMOGRAPHIC INSIGHTS FROM SPOUSAL VERSUS RELATED LIVING DONOR KIDNEY TRANSPLANTATION (ISN-WCN 2026) - "Basiliximab induction was used in 91.3% (n = 21) of spousal and 45.7% (n = 42) of related transplants (p < 0.0001)...Given the relatively younger age of spousal donors, vigilant long-term follow-up is warranted to ensure donor safety and renal health. Overall, spousal donation represents a viable strategy to bridge the living donor gap without compromising long-term outcomes."

Clinical • Infectious Disease • Nephrology • Transplant Rejection • Transplantation

PATHOLOGICAL INSIGHTS INTO ONE-YEAR PROTOCOL BIOPSIES: INFLUENCE OF INDUCTION IMMUNOSUPPRESSION IN KIDNEY TRANSPLANTATION (ISN-WCN 2026) - "However, there were no significant differences of the occurrence of de novo donor specific antibody (DSA) and subclinical rejection between them.Conclusion Although kidney function is stable within one-year after transplant, protocol biopsies accounts for potential pathological changes. This study showed that induction immunosuppressant type was not significantly associated with the development of de novo DSA and subclinical rejection, but use of basiliximab was associated with more pronounced chronic allograft injury than thymoglobulin."

Biopsy • Clinical • Antibody-mediated Rejection • Fibrosis • Glomerulonephritis • Immunology • Transplantation

IS IT WORTH TREATING LATENT TUBERCULOSIS IN POTENTIAL LIVING DONOR RENAL TRANSPLANT RECIPIENTS WITH IGRA POSITIVITY IN MYANMAR? (ISN-WCN 2026) - "Either anti-thymocyte globulin or basiliximab was used as induction therapy. They received corticosteroids, tacrolimus and mycophenolate mofetil as immunosuppressive therapy...They did have neither clinical symptoms nor new radiological features suggestive of pulmonary tuberculosis till 3 years after transplant.Table (1). Possible predisposing factor for latent tuberculosis in potential living donor renal transplant recipients with IGRA positivity (n=32)Conclusion Prescribing isoniazid and rifampicin therapy for 3 months to potential living donor renal transplant recipients with latent tuberculosis (IGRA positivity) in Myanmar was safe and effective to prevent pulmonary tuberculosis till 3 years after transplant."

Clinical • Cough • Diabetes • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Nephrology • Renal Disease • Respiratory Diseases • Transplantation • Tuberculosis

CIRCULATING NEPHRIN ANTIBODIES AND POST-TRANSPLANT RECURRENCE OF DIFFUSE PODOCYTOPATHIES: A SYSTEMATIC REVIEW AND POOLED INDIVIDUAL PATIENT DATA ANALYSIS (ISN-WCN 2026) - "96% of them received basiliximab induction...Fifty-two (80%) underwent plasma exchange and 11 (17%) received rituximab for antibody depletion prophylaxis...The antibody titer may help guide pre-transplant intervention and post-transplant monitoring. Prospective multicenter validation is warranted to identify appropriate timing of testing, standard cut-off point to establish universal protocols for antibody-guided prevention of recurrence and to better illustrate allograft survival outcome."

Clinical • Post-transplantation • Review • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • Transplantation

RENAL TRANSPLANTATION IN ELDERLY PATIENTS AGED 65 YEARS AND OLDER: SHORT-TERM CLINICAL OUTCOMES FROM A SINGLE CENTER EXPERIENCE (ISN-WCN 2026) - "Induction immunosuppressive therapy was performed with basiliximab or thymoglobulin...Infection was the main cause of unfavorable outcomes. Additionally, the duration of dialysis before kidney transplantation was associated with patient mortality following the operation."

Clinical • Clinical data • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Diabetes • Diabetic Nephropathy • Glomerulonephritis • Infectious Disease • Lupus Nephritis • Metabolic Disorders • Nephrology • Pulmonary Arterial Hypertension • Transplant Rejection • Transplantation • Vascular Neurology

A CASE OF ANTI-NEPHRIN AUTOANTIBODIES POSITIVE FSGS RECURRING IMMEDIATELY AFTER KIDNEY TRANSPLANTATION, WITH DARATUMUMAB ADMINISTRATION FAILING TO PREVENT RENAL FUNCTION LOSS (ISN-WCN 2026) - "Treatment with steroids, rituximab (RTX), and LDL apheresis, but treatment was unsuccessful. Hemodialysis started on July 13, and the patient was admitted to the hospital on November 7 for living donor kidney transplantation.In addition to RTX, Basiliximab, mycophenolate mofetil, and tacrolimus, as well as plasma exchange and IVIG...This may be due to the already lost renal function or the possibility of antibody leakage via low-selectivity proteinuria. Japan Renal Transplantation Physician Association"

Clinical • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Inflammation • Transplantation

THE DILEMMA OF INDUCTION IMMUNOSUPPRESSION IN LOW IMMUNOLOGICAL RISK KIDNEY TRANSPLANT RECIPIENTS- A PROSPECTIVE RANDOMISED STUDY FROM EASTERN INDIA COMPARING BASILIXIMAB VERSUS NO INDUCTION IMMUNOSUPPRESSION (ISN-WCN 2026) - "Adjusted five year graft survival were similar in both groups. Adjusted patient death risk was found to be lower (HR 0.42, 95%CI 0.30- 0.74, p= 0.04) in the basiliximab group.Conclusion Perioperative induction with basiliximab in low immunological risk kidney transplant recipients had lower rejection and lower patient death risk."

Clinical • Transplant Rejection • Transplantation

INCIDENCE OF CYTOMEGALOVIRUS INFECTION OR DISEASE USING VALGANCICLOVIR PROPHYLAXIS OR PREEMPTIVE THERAPY IN LIVING-DONOR KIDNEY TRANSPLANT RECIPIENTS AT INTERMEDIATE RISK FOR CMV ON BASILIXIMAB-BASED REGIMEN (ISN-WCN 2026) - "These results support adapting preventive strategies to available resources and diagnostic capacity. In settings with reliable virological monitoring, PT may be a cost-effective alternative, reducing unnecessary antiviral exposure without compromising efficacy."

Clinical • Cytomegalovirus Infection • Infectious Disease • Transplantation

IMPACT OF DONOR APOL1 VARIANTS ON LONG-TERM GRAFT SURVIVAL IN BRAZILIAN LIVING KIDNEY TRANSPLANTATION: INTERIM ANALYSIS OF THE BRIDGES-APOL1 STUDY (ISN-WCN 2026) - "Induction therapy with thymoglobulin or basiliximab was used in 31.9% of recipients. Maintenance immunosuppression predominantly included a calcineurin inhibitor combined with azathioprine (69.8%), with no significant differences between groups...The prevalence of risk variants was consistent with previous studies involving relatives of dialysis patients. The presence of at least one APOL1 risk variant independently increased the long-term risk of graft loss by 63%, highlighting the potential clinical relevance of donor genetic screening in kidney transplantation."

Transplantation

TACROLIMUS PLASMAPHERESIS PROTOCOL FOR KIDNEY TRANSPLANTATION IN ATYPICAL HEMOLYTIC UREMIC SYNDROME CFHR1/CFHR3 DELETION ASSOCIATED DISEASE (ISN-WCN 2026) - "So we used alternative protocol of pre-transplantation plasmapheresis , basiliximab induction and triple immunosuppression using tacrolimus , prednisolone and mycophenolate sodium.Methods 23 year old male medical student presented with severe headache, malignant hypertension, seizures, diminished vision, and breathlessness at rest. Patient maintained stable renal function with controlled blood pressure on reduced antihypertensive regimen.This case demonstrates successful renal transplantation in genomically-confirmed aHUS with severe neurological and cardiovascular manifestations using cost-effective tacrolimus-plasmapheresis protocol as alternative to eculizumab. The CFHR1/CFHR3 deletion represents high recurrence risk, yet excellent early outcomes were achieved.This approach offers viable treatment of genomically-confirmed aHUS with pre-transplantation plasmapheresis, basiliximab and triple immunosuppression (Tacrolimus, mycophenolate ,prednisolone) for..."

Clinical • Atypical Hemolytic Uremic Syndrome • Cardiovascular • CNS Disorders • Complement-mediated Rare Disorders • Epilepsy • Gastrointestinal Disorder • Hypertension • Nephrology • Respiratory Diseases • Retinal Disorders • Transplantation • CFHR3

PATIENT AND GRAFT SURVIVAL RATES AT FIVE YEARS FOLLOWING KIDNEY TRANSPLANTATION IN ETHIOPIA (ISN-WCN 2026) - "Basiliximab was the induction regimen for 93.5%...Donor 24 hour urinary protein level, record of graft rejection and number of hospital admissions predicted reduced five year death censored graft survival with OR (95% CI) of 0.98 (0.96 – 0.99), 0.01(0.001-0.1) and 0.39 (0.22 – 0.71) respectively.Conclusion Five year survival rate of recipients at the National Transplantation Center of Ethiopia is acceptable. The death censored graft survival rate at five years is comparable to those in developed regions."

Clinical • Infectious Disease • Transplant Rejection • Transplantation

CLINICAL OUTCOMES OF PAEDIATRIC RENAL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE (ISN-WCN 2026) - "Induction- not given – 31(62%), Basiliximab-12(24%), ATG- 7(14%)...Mean duration of graft failure – 63.45months, death – 69.33months. CNI toxicity – mean tacrolimus level – 13ng/ml, infections – 8.77ng/ml and Rejection – 3.22ng/ml.Conclusion This study outlines post-transplant complications in pediatric recipients, emphasizing the absence of induction increased rejection rate and careful CNI monitoring to prevent toxicity and infections."

Clinical • Clinical data • Cytomegalovirus Infection • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Infectious Disease • Nephrology • Pediatrics • Transplantation

Successful desensitization in a child with life-threatening reaction to basiliximab retreatment (EAACI 2026) - No abstract available

Clinical • Immunology

Basiliximab preserves renal function after liver transplantation without increasing rejection or graft loss (EASL 2026) - No abstract available

Transplantation

Efficacy and safety of basiliximab in gastrointestinal chronic graft-versus-host disease (PubMed, Zhonghua Xue Ye Xue Za Zhi) - "All patients received initial therapy including glucocorticoids, calcineurin inhibitors, and/or other immunosuppressive agents (eg, mycophenolate mofetil, mesenchymal stem cells, and sirolimus) . Basiliximab may be used to treat GI-cGVHD, with hematologic and infection-related adverse event rates comparable to those of other systemic immunosuppressants. These findings suggest a potential therapeutic option for GI-cGVHD; however, larger prospective studies are needed to further evaluate its safety."

Journal • Retrospective data • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Liver Failure • Nephrology • Neutropenia • Thrombocytopenia • Transplantation

TRANSPLANT ACQUIRED FOOD ALLERGY (TAFA) LEADING TO ANAPHYLACTIC SHOCK IN ORTHOTOPIC HEART TRANSPLANT RECIPIENT (ACC 2026) - "She had received peri-operative basiliximab induction and was maintained on standard immunosuppression...She was treated with epinephrine, methylprednisolone, and diphenhydramine. Her immunosuppression regimen was adjusted, and tacrolimus was switched to cyclosporine... TAFA is a rare but potentially fatal complication in HTx recipients. Further research is needed to clarify its pathogenesis, including the role of immunosuppression, donor immune cell transfer, and dysbiosis, to improve prevention and risk stratification."

Clinical • Allergy • Cardiovascular • CNS Disorders • Congestive Heart Failure • Food Hypersensitivity • Heart Failure • Immunology • Solid Organ Transplantation • Transplantation • Vascular Neurology